Acetylsalicylic acid as an anti-platelet agent: what forms should be used, according to evidence-based medicine?
This analytic paper reviews the evidence on effectiveness, benefits and limitations of one of the best-studied antiplatelet agents – acetylsalicylic acid (ASA). The results of clinical trials, together with so called “gastro-toxicity” of ASA, or Aspirin, and a need for long-term anti-platelet therap...
Main Author: | O. V. Averkov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«SILICEA-POLIGRAF» LLC
2010-04-01
|
Series: | Кардиоваскулярная терапия и профилактика |
Subjects: | |
Online Access: | https://cardiovascular.elpub.ru/jour/article/view/2043 |
Similar Items
-
ACETYLSALICYLIC ACID IN PRIMARY AND SECONDARY PREVENTION OF STROKE
by: P. S. Laguta
Published: (2017-05-01) -
ACETYLSALICYLIC ACID: WHAT'S NEW IN THE OLD DRUG?
by: I. V. Zhirov
Published: (2015-12-01) -
ACETYLSALICYLIC ACID: CONTROVERSIAL AND OUTSTANDING ISSUES
by: E. N. Dankovtseva
Published: (2015-09-01) -
ACETYLSALICYLIC ACID IN LOW DOSES FOR SECONDARY PREVENTION OF CARDIO-VASCULAR COMPLICATIONS
by: N. A. Dmitrieva, et al.
Published: (2016-01-01) -
Acetylsalicylic acid in primary and secondary prevention of cardiovascular diseases. Is it all obvious?
by: A. V. Panov, et al.
Published: (2015-12-01)